Participants must have disease that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains or by minimal residual detection; measurable disease is defined as one or more of the following:\r\n* Serum M protein > . G/DL, or\r\n* Urine M protein >  MG/H, and/or\r\n* Serum free light chain (FLC) assay: involved FLC level >  MG/DL with abnormal serum FLC ratio\r\n* >=  plasma cells detectable by multicolor flow cytometry, at a sensitive level of ^- (determined by central review)
Serum free light chain (FLC) >=  mg/dL, provided serum FLC ratio is abnormal in participants who do not have measurable disease by Serum Protein Electrophoresis (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.
Serum free light chain (FLC) assay: involved FLC level ? mg/dL and an abnormal serum FLC ratio (<. or >.).
Patients must have measurable disease defined as at least one of the following:\r\n* Serum M-protein >= . g/dl (>=  g/l)\r\n* Urine M-protein >=  mg/ hours (h)\r\n* Serum free light chain (FLC) assay: involved FLC level >=  mg/dl (>=  mg/l) and an abnormal serum free light chain ratio (< . or > .)\r\n* Quantitative immunoglobulin >  mg/dL, only for immunoglobulin (Ig)A and IgD myeloma when the protein electrophoresis under-represents disease burden\r\n* Biopsy proven plasmacytoma > x cm (should be measured within  days prior to initial investigational agent dosing)
Measurable disease defined by any of following: Serum M-protein >  g/dL; Urine M-protein >  mg/h; Serum free light chain (FLC) assay: involved FLC level > or equal to  mg/dL provided serum FLC ratio is abnormal; subjects who are non-secretors will be considered on a case-by-case basis
Light chain multiple myeloma (MM), for participants without measurable disease in the serum or urine: serum Immunoglobulin (Ig) free light chain (FLC) >=  mg/dL and abnormal FLC ratio
Serum free light chain (FLC) ? mg/dL with abnormal ratio in subjects with unmeasurable disease by serum or urine PEP.
Measurable disease at the time of relapse, defined as a monoclonal immunoglobulin spike on serum electrophoresis of >=  gm/dL (immunoglobulin [IG]G) or >= . gm/dL (IGA) and/or urine monoclonal immunoglobulin spike of >  mg/ hours and/ or involved free light chain (FLC) level >=  mg/dl and the serum FLC ratio is abnormal
Serum free light chain (FLC) >  mg/L of involved FLC
Participants must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains; measurable disease is defined as one or more of the following: serum M-protein >= . g/dL, urine M-protein >=  mg/ hour (h), and/or serum free light chain (FLC) assay: involved FLC level >=  mg/dL with abnormal serum FLC ratio
Measurable disease defined by serum M-protein ? g/dL, or urine light chain ? mg/ hours, or abnormal serum FLC ratio with involved FLC >  mg/dL provided serum FLC ratio is abnormal
The subject has measurable disease with at least one of the following: Serum M-protein >=. gram per deciliter (g/dL) (>= gram per Liter [g/L]); Urine M-protein >= milligram per  hours (mg/h); Serum Free light chain (FLC) assay: Involved FLC level >= mg/dL (>= mg/L) and an abnormal serum free light chain ratio (<. or >.).
Must have at least ONE aspect of measurable disease, defined as one the following: Urine M-protein excretion >= milligram (mg)/ hours, or; Serum M-protein concentration >=. gram (g)/deciliter (dL) (>=. g/Liter), or; Serum free light chain (FLC) assay: involved FLC level >= mg/dL (>= mg/L) and an abnormal serum FLC ratio (<. or >.).
Serum free light chain (FLC) assay: involved FLC assay ?  mg/dL (?  mg/L) and an abnormal serum FLC ratio (< . or > .)
High risk disease defined by all of the following:\r\n* >= % bone marrow plasma cells AND\r\n* Abnormal serum free light chain (FLC) ratio (< . or > .) by serum FLC assay AND\r\n* Monotypic plasma cell S-phase >= .%
Patient is at higher than average risk of progression to active MM, defined as having  or more of the following features:\r\n* Serum M-protein >=  g/dL\r\n* BMPC > % and < %\r\n* Abnormal serum free light chains (FLC) ratio (.-.)
Patients must have measurable MM as defined by at least one of the criteria below\r\n* One or more of these abnormalities defines measurable disease:\r\n* Serum M-protein greater or equal to . g/dl ( g/l)\r\n* Urine M-protein greater or equal to  mg/ hour (h)\r\n* Serum free light chain (FLC) assay: involved FLC level greater or equal to  mg/dl ( mg/l) provided serum FLC ratio is abnormal\r\n* A biopsy-proven plasmacytoma
Patients must have measurable disease as defined as at least one of the following (these baseline laboratory studies for determining eligibility must be obtained within  days prior to enrollment):\r\n* Serum M-protein >= . g/dl (>=  g/l)\r\n* Urine M-protein >=  mg/ h\r\n* Serum free light chains (FLC) assay: involved FLC level >=  mg/dl (>=  mg/l) and an abnormal serum free light chain ratio (< . or > .)\r\n* Biopsy proven plasmacytoma (should be measured within  days of first study drug administration); prior biopsy is acceptable\r\n* If the serum protein electrophoresis is unreliable for routine M-protein measurement, quantitative immunoglobulin levels on nephelometry or turbidimetry will be followed
Criteria for cohort A (recently diagnosed subjects to receive AHCT)\r\n* Must have presence of clonal plasma cells in the bone marrow greater or equal to % or biopsy proven plasmacytoma\r\n* Must have either (a) presence of myeloma protein (M-component) (immunoglobulin [Ig]G or IgA) in serum greater or equal to  g/dl or in urine greater or equal to  mg/ hours (h); or (b) presence of an abnormal serum free light chain (FLC) ratio on the serum FLC assay
Participants must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains; measurable disease is defined as one or more of the following: serum M-protein >=  g/dl (except patients with immunoglobulin [Ig] D or IgA myeloma), urine M-protein >=  mg/ hour (h), and/or serum free light chain (FLC) assay: involved FLC level >=  mg/dl with abnormal serum FLC ratio; for patients with IgD or IgA myeloma, a serum M-protein of greater than or equal to . g/dl will suffice; free light chain patients not measurable by urine or serum evaluation may be considered for inclusion
Patients must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past  months, as confirmed by both of the following:\r\n* Bone marrow plasmacytosis with >= % plasma cells or sheets of plasma cells at any time before initiating study treatment, including a marrow which must be obtained by bone marrow aspiration and/or biopsy within  weeks prior to randomization\r\n* Abnormal serum free light chain ratio (< . or > .) by serum free light chain (FLC) assay; FLC assay must be performed within  days of randomization
Subjects must have measurable disease including at least one of the criteria below: Serum M-protein greater or equal to . g/dL Urine M-protein greater or equal to  mg/ h Serum free light chain (FLC) assay: involved FLC level greater or equal to  mg/dL ( mg/L) provided serum FLC ratio is abnormal -Women of child-bearing potential (WCBP) must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study Part A: Diagnosis of MM with relapsed or refractory disease and have had at least  different prior lines of therapy including proteasome inhibitor (e.g., bortezomib or carfilzomib) and immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide), or have \double refractory\ disease to a proteasome inhibitor and IMiD, defined as progression on or within  days of treatment with these agents
Patients with measurable disease defined as one or more of the following: serum M-protein >= . g/dl, urine M-protein >=  mg/ hour (h), and/or serum free light chain (FLC) assay: involved FLC level >=  mg/dl with abnormal serum FLC ratio
Serum free light chain (FLC) assay: Involved FLC assay ? mg/dL (? mg/L) and an abnormal serum FLC ratio (<. or >.).
Participant has measurable disease at Screening, defined as at least one of the following: Serum M-protein greater than or equal to . g/dL, OR Urine M-protein greater than or equal to  mg in -hours, OR serum immunoglobulin free light chain (FLC) greater than or equal to  mg/dL provided serum FLC ratio is abnormal.
? prior systemic hematologic therapy for a free light chain (FLC) producing hematologic malignancy underlying the initial diagnosis of AL amyloidosis with at least a partial FLC response (PR, VGPR, CR) to treatment deemed stable and not requiring further treatment
Measurable disease as defined by one or more of the following criteria (assessed within  days prior to registration):\r\n* Serum paraprotein >=  g/L (for immunoglobulin A [IgA] patients whose disease can only be reliably measured by serum quantitative immunoglobulin [IgA]: >= . g/L)\r\n* Urine Bence Jones protein: >=  mg/ hours (h) \r\n* Serum light chain assay: Involved free light chain (FLC) level >=  mg/L, provided serum FLC ratio is abnormal
Patients must currently have measurable disease, as defined as:\r\n* Serum M protein >= . g/dl\r\n* Urine M protein >=  mg/h\r\n* Serum free light chain assay: involved free light chain (FLC) level >=  mg/dl (>=  mg/l) provided serum FLC ratio is abnormal\r\n* If no monoclonal protein is detected (non-secretory disease), then > % monoclonal bone marrow plasma cells
Measurable MM disease, defined as one of the following:\r\n* A monoclonal immunoglobulin (Ig) concentration on serum electrophoresis of >= . g/dL for an IgG myeloma, >= . g/dL for an IgD myeloma or >= . g/dL for an IgA myeloma\r\n* Measurable urinary light chain secretion by quantitative analysis of >=  mg/ hours\r\n* Involved serum free light chain (FLC) level >=  mg/dL, provided the serum FLC ratio is abnormal\r\n* Patients with oligo- or non-secretory disease must have bone marrow involvement with at least % plasmacytosis on aspiration
Participants must have myeloma that is measurable; measurable disease is defined as one or more of the following:\r\n* Serum M-protein >= . g/dl,\r\n* Urine M-protein >=  mg/ hour (h), and/or\r\n* Serum free light chain (FLC) assay: involved FLC level >=  mg/dl with abnormal serum FLC ratio
Measurable disease for phase IIa portion only\r\n* Lymphoma (includes cutaneous T-cell lymphoma [CTCL] patients who have no evidence of disease [NED] in skin): computed tomography (CT) or positron emission tomography (PET)/CT by modified Cheson criteria with incorporation of PET\r\n* Multiple myeloma: patient must have measurable disease and therefore must have at least one of the following:\r\n** Serum myeloma protein (M-protein) >= . gm/dL (>=  gm/L)\r\n** Urine M-protein >=  mg/ hours (hr)\r\n** Serum free light chain (FLC) assay: involved FLC >=  mg/dL (>=  mg/L) provided serum FLC ratio is abnormal\r\n* CTCL: Modified Severity-Weighted Assessment Tool (mSWAT) >  or absolute Sezary count >= , cells/uL
Serum free light chain (FLC) assay: involved FLC level ?  mg/dL (?  mg/L), provided that the serum FLC ratio was abnormal.
Serum free light chain (FLC) >  mg/L of involved FLC
Measurable MM disease, defined as one of the following: \r\n* A monoclonal immunoglobulin (Ig) concentration on serum electrophoresis of >= . g/dL for an IgG myeloma, >= . g/dL for an IgD myeloma or . g/dL for an IgA myeloma\r\n* Measurable urinary light chain secretion by quantitative analysis of >=  mg/ hours\r\n* Involved serum free light chain (FLC) level >=  mg/dL, provided the serum FLC ratio is abnormal\r\n* Patients with oligo- or non-secretory disease must have bone marrow involvement with at least % plasmacytosis
Measurable multiple myeloma disease, defined as meeting at least  of the following criteria within  days prior to registration: \r\n* A monoclonal Ig (M-protein) concentration on serum protein electrophoresis (SPEP) of >= . g/dL\r\n* Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of >=  mg/ hours\r\n* Involved serum free light chain (FLC) level >=  mg/dL, provided the serum FLC ratio is abnormal\r\n* Presence of extramedullary plasmacytomas
Involved FLC assay >  mg/dL with abnormal FLC ratio.
Serum free light chains (FLC) assay: Involved FLC level ?  mg/dl (?  mg/l) and an abnormal serum free light chain ratio (< . or > .)
Must have measurable disease, defined by one or more of following: (i) a serum M protein > . g/dl measured by serum protein electrophoresis; (ii) urinary M protein excretion >  mg/ hours; (iii) serum free light chain (FLC) measurement >  mg/dl, provided that the serum FLC ratio is abnormal
Serum free light chain (FLC) >  mg/L of involved FLC
Involved serum free light chain (FLC) level ?  mg/dL, provided the serum FLC ratio is abnormal.
Patients must currently have measurable disease, as defined as:\r\n* Serum M protein >= . g/dl (>=  mg/l) unless IgA >= . g/dL\r\n* Urine M protein >=  mg/h\r\n* Serum free light chain assay: involved free light chain (FLC) level >= mg/dl (>=  mg/l) provided serum FLC ratio is abnormal\r\n* If no monoclonal protein is detected (non-secretory disease), then > % monoclonal bone marrow plasma cells
Patients with measureable disease defined as at least one of the following:\r\n* Serum M-protein >= . g/dl (>=  g/l)\r\n* Urine M-protein >=  mg/ h\r\n* Serum free light chain (FLC) assay: involved FLC level >=  mg/dl (>=  mg/l) and an abnormal serum free light chain ratio (< . or > .)\r\n* Measurable plasmacytoma (prior biopsy is acceptable, should be measured within  days of first study drug administration)
Involved FLC ? mg/dL and abnormal FLC ratio in serum (<. or >.)
Involved FLC level ? mg/dL and abnormal FLC ratio in serum (<. or >.)
Involved FLC level ? mg/dL and an abnormal FLC ratio in serum (<. or >.)
Serum FLC ?  mg/L, provided that the serum FLC ratio is abnormal.
MM that does not express M-protein or serum FLC (i.e., non-secretory MM is excluded; plasmacytomas without M-protein or serum FLC are excluded).
MM\r\n* Absence of monoclonal protein in serum and urine by immunofixation with no current evidence of soft tissue plasmacytoma\r\n* Bone marrow aspirate and biopsy must demonstrate less than  percent clonal plasma cells\r\n* In patients who lack measurable M proteins in the serum and urine being monitored using the free light chain (FLC) levels, the definition of complete response (CR) requires a normalization of the FLC ratio in addition to the above criteria
Part /dose escalation; Histologically or cytologically confirmed diagnosis of Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the  following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within  days of completion of the last therapy. Part  /MM cohort; Histologically or cytologically confirmed diagnosis of: Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the  following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within  days of completion of the last therapy, and has measurable disease with at least one of the following: serum M-protein >=. gram (g)/decilitre (dL) (>= g/Litre (L)), urine M-protein >= milligram (mg)/hour (h). Serum free light chain (FLC) assay: Involved FLC level >= mg/dL (>= mg/L) and an abnormal serum FLC ratio (<. or >.) and biopsy proven plasmacytoma (should be measured within  days of Screening Visit).
Diagnosis of high risk smoldering multiple myeloma (SMM) (per International Myeloma Working Group [IMWG] criteria) for less than or equal to (<=) years with measurable disease, defined as clonal bone marrow plasma cells (BMPCs) greater than or equal to (>=) percent (%) but less than (<)% and  of the following: serum M-protein >= gram per liter (g/L) or urine M-protein >= milligram per  hours (mg/ hours) or involved serum free light chain (FLC) >= milligram per liter (mg/L) and abnormal serum FLC ratio
Serum FLC ratio (involved:uninvolved) >= (the involved FLC must be >= mg/L)
Serum free light chain (FLC) ?  mg/L, provided that the serum FLC ratio is abnormal.
In participants without measurable M-protein in serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP), a serum FLC assay result with involved FLC level >= mg/dL (>= milligram per liter [mg/L]), provided serum FLC ratio is abnormal.
